|
Characteristic
|
|---|
|
Age, years
|
| |
Median (range)
|
62 (31–85)
|
|
Sex, n (%)
|
| |
Male
|
37 (47.4)
|
| |
Female
|
41 (52.6)
|
|
ECOG performance status, n (%)
|
| |
0
|
15 (19.2)
|
| |
1
|
56 (71.8)
|
| |
2
|
7 (9.0)
|
|
Histology, n (%)
|
| |
Adenocarcinoma
|
78 (100)
|
|
Stage, n (%)
|
| |
IV
|
78 (100)
|
|
Brain metastases, n (%)
|
| |
No
|
58 (74.4)
|
| |
Yes
|
20 (25.6)
|
|
Smoking status, n (%)
|
| |
Former
|
22 (28.2)
|
| |
Never
|
51 (65.4)
|
| |
Unknown
|
5 (6.4)
|
|
EGFR mutation status, n (%)
|
| |
Positive
|
6 (7.7)
|
| |
Negative
|
72 (92.3)
|
|
ALK fusion status, n (%)
|
| |
Positive
|
0
|
| |
Negative
|
78 (100)
|
|
Pyrotinib treatment line, n (%)
|
| |
1
|
23 (29.5)
|
| |
2
|
15 (19.2)
|
| |
≥ 3
|
40 (51.3)
|
|
Previous afatinib therapy
|
| |
Yes
|
21 (26.9)
|
| |
No
|
57 (73.1)
|
|
HER2 mutation, n (%)
|
| |
Exon 20 mutation
|
62 (79.5)
|
| |
Non-exon 20 mutation
|
16 (20.5)
|
- ECOG Eastern Cooperative Oncology Group
